Background: With the help of Japan, the Center for Research and Production of vaccines and biologicals, Hanoi has received a WHO standard measles vaccine production technology, including techniques in the examination of vaccine quality. Therefore, it is needed to be initiative on production of measles antibody. Objective: Study on production of measles antibody in rabbits and selecting the appropriate antibody for production of high titre antibody, which meets the standard of vaccine quality control in Vietnam. Subject and methods: Using the measles antigen from Edmonston and AIK-C strains, which were provided by the Kitasato Institute, to produce measles antibody. Making immunoreaction in rabbits and determination of neutralization antibody titre. Results and Conclusion: Measles antigen of Edmonston Vero 7/P2 strain used in the production of measles antibody in rabbit created the highest antibody titre in comparison with AIK-C strain from vero cell and FL cell supplied by the Kitasato Institute of Japan. Antibody titre of Edmonston Vero 7/P2 strain reached up to 1/8192 and met the sera standard required for measles vaccine quality control, it is similar to the measles sera to be produced from the Kitasato Institute.
measles antibody ; antibody titre

PURPOSE: With the implementation of measles vaccination programs, the number of patients with measles has decreased. However, epidemics still occur with high morbidity in infants less than 1 year of age. This fact calls for the establishment of optimal preventive measures against measles. The study was carried out to determine the effect of measles vaccination on an infant immunized before one year of age, any the measles immunity conferred by MMR. METHODS: Seventy-seven healthy infants (13.7 +/- 1.8 months) were immunized with the MMR vaccine (Triviraten Berna : Edmonston-Zagreb strain, Rubini strain, Wistar RA 27/3 strain), 50 of the infants have received measles vaccine before turning one-year old. The antibody titers of measles-specific IgG were measured by enzyme immunoassay. RESULTS: The antibody titers before and after MMR vaccination were significantly higher in infants previously immunized with measles vaccine compared to those not immunized. However, the greater number of infants not previously immunized with measles vaccine showed significant increase of measles antibody titers after MMR vaccination compared to those previously immunized with measles vaccine. Measles vaccine failure occurred in 6 infants (12.0%), all of whom acquired measles immunity following MMR vaccination. Measles immunogenicity to MMR did not differ with respect to the age of previous measles vaccination. CONCLUSION: The results indicate that measles vaccination in infants less than 1 year of age will not decrease the measles immunity following MMR vaccination, and it is suitable to vaccinate against measles in infants between 6-12 months of age, if needed.
Antibody Formation* ; Humans ; Immunization* ; Immunoenzyme Techniques ; Immunoglobulin G ; Infant ; Measles Vaccine ; Measles* ; Measles-Mumps-Rubella Vaccine ; Vaccination*

PURPOSE: With the implementation of measles vaccination programs, the number of patients with measles has decreased. However, epidemics still occur with high morbidity in infants less than 1 year of age. This fact calls for the establishment of optimal preventive measures against measles. The study was carried out to determine the effect of measles vaccination on an infant immunized before one year of age, any the measles immunity conferred by MMR. METHODS: Seventy-seven healthy infants (13.7 +/- 1.8 months) were immunized with the MMR vaccine (Triviraten Berna : Edmonston-Zagreb strain, Rubini strain, Wistar RA 27/3 strain), 50 of the infants have received measles vaccine before turning one-year old. The antibody titers of measles-specific IgG were measured by enzyme immunoassay. RESULTS: The antibody titers before and after MMR vaccination were significantly higher in infants previously immunized with measles vaccine compared to those not immunized. However, the greater number of infants not previously immunized with measles vaccine showed significant increase of measles antibody titers after MMR vaccination compared to those previously immunized with measles vaccine. Measles vaccine failure occurred in 6 infants (12.0%), all of whom acquired measles immunity following MMR vaccination. Measles immunogenicity to MMR did not differ with respect to the age of previous measles vaccination. CONCLUSION: The results indicate that measles vaccination in infants less than 1 year of age will not decrease the measles immunity following MMR vaccination, and it is suitable to vaccinate against measles in infants between 6-12 months of age, if needed.
Antibody Formation* ; Humans ; Immunization* ; Immunoenzyme Techniques ; Immunoglobulin G ; Infant ; Measles Vaccine ; Measles* ; Measles-Mumps-Rubella Vaccine ; Vaccination*

No abstract available.
Antibody Formation* ; Child* ; Diploidy* ; Humans* ; Immunization* ; Measles ; Measles-Mumps-Rubella Vaccine* ; Mumps ; Rubella ; Vaccination

PURPOSE: This study (NCT00751348) evaluated the immunogenicity and safety of a combined measles-mumps-rubella-varicella (MMRV) vaccine compared to co-administration of measles-mumps-rubella and varicella (MMR+V) vaccines in Korean children during their second year of life. MATERIALS AND METHODS: Healthy children aged 11-24 months received one dose of MMRV or MMR+V. Antibody titers against measles, mumps and rubella were measured using enzyme-linked immunosorbent assay and against varicella using an immunofluorescence assay. Parents/guardians recorded adverse events in diary cards for up to 43 days post-vaccination. The primary objective was to demonstrate non-inferiority of MMRV to MMR+V for all antigens in terms of seroconversion rates (SCRs), defined as a group difference with a lower limit of the 95% confidence interval (CI)>-10%. RESULTS: Of 474 subjects enrolled, 458 (MMRV, 301; MMR+V, 157) were included in the according-to-protocol cohort. For measles (98.0% vs. 99.4%), rubella (99.7% vs. 100%) and varicella (98.9% vs. 100%) SCRs, the lower limits of the 95% CIs for group differences were greater than -10%; however, for mumps SCRs (88.8% vs. 94.2%), it was -10.40%. The primary objective of non-inferiority in mumps SCRs was therefore not met, although the observed group difference in a post-hoc analysis of anti-mumps antibodies using a plaque reduction neutralization assay was 0.39% with a 95% CI lower limit of -4.03%. Adverse events occurred at comparable frequencies for both groups, except for more frequent fever in MMRV recipients. CONCLUSION: Based on the pre-specified non-inferiority criterion, SCRs of the MMRV vaccine were non-inferior to that elicited by MMR+V vaccines for all antigens except mumps.
Antibodies ; Chickenpox ; Child* ; Cohort Studies ; Enzyme-Linked Immunosorbent Assay ; Fever ; Fluorescent Antibody Technique ; Humans ; Korea ; Measles ; Mumps ; Rubella ; Vaccines

Asthma is considered a chronic inflammatory airway disease. Mounting evidence reports that patients with asthma are at significantly higher risk of developing communicable diseases such as invasive pneumococcal disease, Haemophilus influenza, varicella, measles, pertussis and tetanus. While impaired innate immunity may play a role in increased risk of developing these infections, suboptimal adaptive immune responses have also been reported to play a role in asthmatic subjects with regard to increased risk of infections. This review discusses the currently underrecognized immunological effect of asthma on antibody to vaccines and recommends that clinicians be aware of less optimal antibody production in response to vaccines in subjects with asthma.
Antibody Formation ; Asthma* ; Chickenpox ; Communicable Diseases ; Haemophilus ; Humans ; Immunity, Innate ; Influenza, Human ; Measles ; Tetanus ; Vaccines* ; Whooping Cough

BACKGROUND: Bone marrow transplantation (BMT) has become a significant treatment modality for hematopoietic and solid organ malignancy. Recipients of BMTs lose immunity to measles-mumps-rubella (MMR) and hepatitis B infections which are preventable with vaccination. There is no consensus regarding a vaccination schedule after BMT and time of vaccination is variable according to each institution. We analyzed sequential changes in antibody titers of MMR and hepatitis B during the first year after BMT in an attempt to identify the time, dose, and needs for revaccination. METHODS: Total 20 patients with hematologic malignancies were studied. Serum levels of IgG antibodies of MMR and hepatitis B virus (HBV) were determined every three months post-BMT by enzyme immunoassay (EIA), chemical luminescence immunoassay (CLIA) and immunofluorescence assay (IFA). RESULTS: IgG antibody levels of measles, rubella, HBV were 1:746, 80 85 IU/mL, 214 343 IU/L before BMT, declined to 1:633, 18 11 IU/mL, 4 6 IU/L one year after BMT, respectively. All the antibody levels were still above cut-off value for positive immunity. Mumps antibody titers were 1:62 before BMT, declined to 1:25 significantly from 6 months after BMT, but the antibody level was still above cut-off value. CONCLUSION: Antibody titers of MMR and hepatitis B decline during the first year after BMT, but the levels are still above cut-off value. Thus, the timing of revaccination should be after the first year post-transplantation. Long-term studies are needed to determine the optimal time for revaccination.
Antibodies ; Appointments and Schedules ; Bone Marrow Transplantation* ; Bone Marrow* ; Consensus ; Fluorescent Antibody Technique ; Hematologic Neoplasms ; Hepatitis B virus* ; Hepatitis B* ; Hepatitis* ; Humans ; Immunization, Secondary ; Immunoassay ; Immunoenzyme Techniques ; Immunoglobulin G ; Korea* ; Luminescence ; Measles* ; Mumps* ; Rubella* ; Vaccination